Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managin...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Giorgio Walter Canonica, Francesco Blasi, Pierluigi Paggiaro, Gianenrico Senna, Giovanni Passalacqua, Antonio Spanevello, Stefano Aliberti, Diego Bagnasco, Marco Bonavia, Matteo Bonini, Luisa Brussino, Caterina Bucca, Maria F. Caiaffa, Cecilia Calabrese, Gianna Camiciottoli, Marco Caminati, Giovanna E. Carpagnano, Cristiano Caruso, Stefano Centanni, Maria E. Conte, Angelo G. Corsico, Lorenzo Cosmi, Maria T. Costantino, Nunzio Crimi, Simona D’Alò, Maria D'Amato, Stefano Del Giacco, Alessandro Farsi, Elisabetta Favero, Maria P. Foschino Barbaro, Gabriella Guarnieri, Giuseppe Guida, Manuela Latorre, Salvatore Lo Cicero, Carlo Lombardi, Luigi Macchia, Francesco Mazza, Francesco Menzella, Manlio Milanese, Marcello Montagni, Paolo Montuschi, Eleonora Nucera, Roberta Parente, Vincenzo Patella, Girolamo Pelaia, Laura Pini, Francesca Puggioni, Luisa Ricciardi, Fabio L.M. Ricciardolo, Luca Richeldi, Erminia Ridolo, Giovanni Rolla, Pierachille Santus, Nicola Scichilone, Giuseppe Spadaro, Andrea Vianello, Vittorio Viviano, Mona R. Yacoub, Maria C. Zappa, Enrico Heffler
Формат:	Өгүүллэг
Хэл сонгох:	English
Хэвлэсэн:	Elsevier 2020-10-01
Цуврал:	World Allergy Organization Journal
Нөхцлүүд:	Severe asthma Biologics Oral corticosteroids Real-life Registr
Онлайн хандалт:	http://www.sciencedirect.com/science/article/pii/S1939455120303677

Ижил төстэй зүйлс

Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey
-н: Claudia Crimi, зэрэг
Хэвлэсэн: (2023-11-01)

Nasal polyps impact in severe asthma patients: evidences from the SANI
-н: Giorgio Walter Canonica, зэрэг
Хэвлэсэн: (2020-08-01)

Economic impact of a more extensive use of FENO testing on the Italian population with asthma
-н: Carla Rognoni, зэрэг
Хэвлэсэн: (2023-06-01)

Asthma severity: the patient’s point of view
-н: Gabriella Guarnieri, зэрэг
Хэвлэсэн: (2024-12-01)

Is Bronchiectasis (BE) Properly Investigated in Patients with Severe Asthma? A Real-Life Report from Eight Italian Centers
-н: Giovanna Elisiana Carpagnano, зэрэг
Хэвлэсэн: (2023-10-01)

Clinical-economic impact of mepolizumab in patients with severe hypereosinophilic asthma
-н: Diego Bagnasco, зэрэг
Хэвлэсэн: (2020-08-01)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life
-н: Diego Bagnasco, зэрэг
Хэвлэсэн: (2021-02-01)

Severe asthma: One disease and multiple definitions
-н: Diego Bagnasco, MD, PhD, зэрэг
Хэвлэсэн: (2021-11-01)

Critical evaluation of asthma biomarkers in clinical practice
-н: Giuseppe Guida, зэрэг
Хэвлэсэн: (2022-10-01)

Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center
-н: Paolo Solidoro, зэрэг
Хэвлэсэн: (2022-01-01)

Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort
-н: Marco Caminati, MD, зэрэг
Хэвлэсэн: (2024-08-01)

Phenotype overlap in the natural history of asthma
-н: Fabio L.M. Ricciardolo, зэрэг
Хэвлэсэн: (2023-05-01)

Minimal clinically important difference for asthma endpoints: an expert consensus report
-н: Matteo Bonini, зэрэг
Хэвлэсэн: (2020-06-01)

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders
-н: Diego Bagnasco, зэрэг
Хэвлэсэн: (2023-08-01)

Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies
-н: Giorgio Walter Canonica, зэрэг
Хэвлэсэн: (2021-09-01)

Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: Evidence from the Severe Asthma Network in Italy (SANI)
-н: Giorgio Walter Canonica, MD, зэрэг
Хэвлэсэн: (2025-01-01)

Tezepelumab: patient selection and place in therapy in severe asthma
-н: Francesco Menzella, зэрэг
Хэвлэсэн: (2024-04-01)

Treatment strategies for asthma: reshaping the concept of asthma management
-н: Alberto Papi, зэрэг
Хэвлэсэн: (2020-08-01)

Omalizumab as add‐on therapy in a patient with severe asthma and OSA
-н: Giulia Scioscia, зэрэг
Хэвлэсэн: (2020-03-01)

Efficacy of Mepolizumab in patients with previous Omalizumab treatment failure: real life observation
-н: Diego Bagnasco, зэрэг
Хэвлэсэн: (2020-08-01)

The evidence on tiotropium bromide in asthma: from the rationale to the bedside
-н: Dejan Radovanovic, зэрэг
Хэвлэсэн: (2017-05-01)

Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
-н: Corrado Pelaia, зэрэг
Хэвлэсэн: (2023-03-01)

Vascular remodeling and TSLP/angiogenin overexpression in severe mixed asthma
-н: Francesca Bertolini, зэрэг
Хэвлэсэн: (2025-02-01)

Erratum to: The evidence on tiotropium bromide in asthma: from the rationale to the bedside
-н: Dejan Radovanovic, зэрэг
Хэвлэсэн: (2017-06-01)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
-н: Erminia Ridolo, зэрэг
Хэвлэсэн: (2020-10-01)

Brittle asthma
-н: O. Toungoussova, зэрэг
Хэвлэсэн: (2016-02-01)

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
-н: Alessandra Vultaggio, зэрэг
Хэвлэсэн: (2023-05-01)

Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma–COPD overlap syndrome phenotype
-н: Lacedonia D, зэрэг
Хэвлэсэн: (2017-06-01)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
-н: Giovanna Elisiana Carpagnano, зэрэг
Хэвлэсэн: (2021-03-01)

SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma
-н: G. Senna, зэрэг
Хэвлэсэн: (2017-04-01)

Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis
-н: Maria D'Amato, зэрэг
Хэвлэсэн: (2022-05-01)

Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study
-н: Paolo Solidoro, зэрэг
Хэвлэсэн: (2019-04-01)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
-н: Francesco Menzella, зэрэг
Хэвлэсэн: (2016-12-01)

Positioning tezepelumab for patients with severe asthma: from evidence to unmet needs
-н: Carlo Lombardi, зэрэг
Хэвлэсэн: (2024-11-01)

The extracellular matrix of the lung and airway responsiveness in asthma
-н: F.G. Salerno, зэрэг
Хэвлэсэн: (2016-01-01)

Alexithymia and asthma: a systematic review
-н: Orlando Silvestro, зэрэг
Хэвлэсэн: (2023-08-01)

Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series
-н: Carlo Lombardi, зэрэг
Хэвлэсэн: (2024-07-01)

“Characteristics of patients admitted to emergency department for asthma attack: a real-LIFE study”
-н: Laura Losappio, зэрэг
Хэвлэсэн: (2019-06-01)

Interleukin-5 in the Pathophysiology of Severe Asthma
-н: Corrado Pelaia, зэрэг
Хэвлэсэн: (2019-12-01)

Role of Leukotrienes and Leukotriene Modifiers in Asthma
-н: Paolo Montuschi
Хэвлэсэн: (2010-06-01)